Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis.
Novo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate with glucose monitoring systems and glucose meters.
The FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group of new class of drugs for the condition.
The FDA has finally approved Teva’s potential blockbuster migraine drug Ajovy after months of delays due to concerns about the manufacturing plant operated by the company’s partner, Celltri
It all looked so good in 2011 when Eli Lilly agreed a deal with French biotech Adocia to develop an ultra-rapid insulin, in a deal worth up to $165 million.